John Kulman
Chief Scientific Officer Zag Bio
John D. Kulman, Ph.D. is an experienced drug developer with over 20 years of scientific leadership experience in academia and industry and a track record of advancing both first- and best-in-class biologics and gene editing therapies to the clinic and through to marketing approval, including Eloctate®, Alprolix®, Altuviiio®, and Casgevy®. Most recently, Dr. Kulman served on the executive leadership team at CRISPR Therapeutics where he led Discovery Research and Translational Genomics. Previously, he was the Head of Research at Codiak Biosciences, where he pioneered the development of engineered therapeutic exosomes. Prior to that he held positions of increasing scientific leadership at Biogen. He holds an M.Phil. in Biochemistry from the University of Cambridge and a Ph.D. in Biochemistry from the University of Washington.
Seminars
- Comparison of regulatory T cells, peripheral regulatory T cells, and alternative immunetolerance mechanisms, highlighting their distinct biology and therapeutic relevance
- Reviewing current preclinical and emerging clinical evidence, outlining how each approach contributes to immune modulation
- Insights into key challenges, translational hurdles, and notable successes that are shaping the future development of targeted immunotherapies
